Pfizer (PFE)
(Delayed Data from NYSE)
$28.30 USD
-0.41 (-1.43%)
Updated Aug 16, 2024 04:01 PM ET
After-Market: $28.29 -0.01 (-0.04%) 5:26 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$28.30 USD
-0.41 (-1.43%)
Updated Aug 16, 2024 04:01 PM ET
After-Market: $28.29 -0.01 (-0.04%) 5:26 PM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Zacks News
Horizon Pharma (HZNP) Q2 Earnings & Sales Top, Raises View
by Zacks Equity Research
Horizon Pharma plc (HZNP) topped both earnings and sales estimate in second-quarter 2017 and raised its sales guidance for 2017.
The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Pfizer, Intel, Chevron and Exxon Mobil
Q2 Earnings Fail to Impress Pharma ETF
by Sweta Killa
The string of earnings beat failed to boost pharma ETFs.
Dow 30 Stock Roundup: Apple Impresses, Pfizer Beats on Earnings
by Swarup Gupta
The Dow breached the psychological 22,000 barrier during a week of strong gains.
Market News For August 04, 2017
by Zacks Equity Research
The blue-chip index registered its 33rd record for 2017 to finish above the 22,000 threshold yet again on a day marked by losses for other benchmarks.
Pharma Stock Roundup: Mixed 2Q Results from Pfizer, Bristol-Myers Announces IO Deals
by Arpita Dutt
Pfizer's (PFE) results were mixed while Teva had a dismal quarter with the company missing estimates as well as cutting its outlook and guidance.
Momenta (MNTA) Q2 Loss In Line with Estimates, Sales Beat
by Zacks Equity Research
Momenta Pharmaceuticals Inc (MNTA)'s loss per share came in line with estimates in the second quarter of 2017 while sales beat estimates driven by Glatopa 20mg.
Aerie (AERI) Reports Narrower-Than-Expected Loss in Q2
by Zacks Equity Research
Aerie Pharmaceuticals, Inc.'s (AERI) narrower-than-expected loss in the second quarter was encouraging.
Company News For August 02, 2017
by Zacks Equity Research
Companies in the news are: XRX,ADM,RCL,PFE
Can DENTSPLY Sirona (XRAY) Deliver a Beat in Q2 Earnings?
by Zacks Equity Research
DENTSPLY Sirona's (XRAY) results are likely to be boosted by surging dental & healthcare consumables space in the yet-to-be-reported second quarter.
Q2 Earnings From UA, PFE And ADM
by Zacks Equity Research
Q2 Earnings From UA, PFE And ADM
Pfizer (PFE) Surpasses Q2 Earnings Estimates, Misses Sales
by Zacks Equity Research
Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.
Q2 Earnings Tuesday: Mixed Bag for Most
by Mark Vickery
UnderArmour (UAA), Pfizer (PFE), Archer Daniels Midland (ADM), among others, hit the tape this morning.
Becton, Dickinson (BDX) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Becton, Dickinson's (BDX) second-quarter performance faces risks from unfavorable foreign exchange rate.
Pfizer (PFE) Tops Q2 Earnings Estimates, Misses Sales
by Zacks Equity Research
Pfizer, Inc. (PFE) beat expectations for earnings while missing the same for sales in Q2. It raised the lower end of its 2017 adjusted earnings guidance but kept the revenue expectations intact.
Key FDA Events to Watch Out for in Aug 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Dynavax's (DVAX) hepatitis B vaccine?
Allergan (AGN) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan plc's (AGN) Q2 sales are likely to be driven by new as well as established products and international growth, earnings will likely be driven by sales growth and cost control.
Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY
by Zacks Equity Research
The Medical sector has carried on the momentum of its first quarter performance so far this earnings season but lagged the overall market.
What's in the Cards for Immune Design (IMDZ) in Q2 Earnings?
by Zacks Equity Research
Immune Design Corp (IMDZ) is likely to focus on data from studies on its pipeline candidates- CMB305 and G100 in Q2.
Apple, Pfizer and Yum Brands are part of Zacks Earnings Preview
by Zacks Equity Research
Apple, Pfizer and Yum Brands are part of Zacks Earnings Preview
Can Cardinal Health (CAH) Pull a Surprise in Q4 Earnings?
by Zacks Equity Research
Despite an upbeat outlook, cut-throat competition in the niche space and pricing pressure in generics portfolio are likely to mar Cardinal Health's (CAH) results in the fourth quarter.
Pharma Stock Roundup: Q2 Earnings Results from Merck, Lilly, Bristol-Myers & More
by Arpita Dutt
Companies like AstraZeneca (AZN) and Lilly saw their shares fall after the release of second quarter results.
Upcoming Earnings Reports to Watch: AAPL, PFE, TWX, KHC
by Ryan McQueeney
We are looking ahead to next week to target the most important upcoming reports. Check out the latest on Apple (AAPL), Pfizer (PFE), Time Warner (TWX), and Kraft Heinz (KHC) ahead of their earnings report dates.
Merck (MRK) Beats on Q2 Earnings and Sales, Keeps 2017 View
by Zacks Equity Research
Merck & Co., Inc. (MRK) beat estimates for both earnings and sales in Q2 mainly backed by strong sales of PD-1 inhibitor, Keytruda.
Why Pfizer Inc. (PFE) Might Surprise This Earnings Season
by Zacks Equity Research
Pfizer Inc. (PFE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.